Navigating the Challenges of Rare Disease Therapies
Understanding the Valuable Role of a Specialty Pharmacy Solutions Provider
Looking Ahead to 2024: Robust Outlook for Specialty Drugs, Cell and Gene Therapies
Significant industry trends worth watching in the new year.
Celebrating the Tireless Efforts of Family Caregivers
Recognizing and honoring the invaluable contributions of family caregivers.
Breaking Ground in NASH Treatment: Resmetirom on the Horizon
Development in treatment for patients with non-alcoholic steatohepatitis (NASH).
HUB & Patient Support Solutions Complement Pre-Commercialization Services
AscellaHealth’s expanded HUB/ Patient Support Services for Life Sciences manufacturers are recognized as the best-in-class outsourced solutions for successful medication access, compliance and persistency and enhanced outcomes.
Re-Think. Re-Consider. Re-Calibrate.
2023 Go-to-Market Strategies for Launching Specialty Drugs, Gene & Cell Therapies
Something for Everyone at Rare Disease Week on Capitol Hill
Rare Disease Week on Capitol Hill, February 28th through March 2nd, 2023.
AscellaHealth Specialty Pharmacy Distribution & Market Access Webinar Highlights
Experts provide in-depth insights on commercialization strategy, distribution models and demonstrating therapeutic value of Rare Disease & Gene/Cell therapies for patients, payers, and providers.
Patient-First Approach: Initial Step in Addressing Nation’s Health Inequities
Removing barriers to reach Health equity.
Optimizing Treatment for Rare Genetic Condition: Cushing’s Syndrome
Cushing’s syndrome, a rare endocrine disorder and FDA approved treatments.
Update on Gene Therapy and Genome-Editing for Rare Diseases
There’s some upbeat news in gene therapy and genome-editing treatments.